Akademik Veri Yönetim Sistemi
13th International Drug Chemistry Conference, Antalya, Türkiye, 6 - 09 Şubat 2025, ss.13, (Özet Bildiri)
Prostate diseases such as prostate cancer and benign prostatic hyperplasia (BPH) are leading
causes of morbidity in the elderly male population over the world. These are progressive
pathological disorders that are generally observed in about 50% of men aged 50 years and
about 80% of men aged 70 years. The main treatment strategies for prostate cancer, androgen
ablation therapy and chemotherapy, can not provide a significant survival rate in men with
metastatic or advanced local diseases. When looking at the current treatment strategies used
in BPH therapy, which are not yet fully effective, can be divided into two groups: medical and
surgical treatment methods. While surgical ablation, such as transurethral resection, has been
accepted as the only conventional BPH treatment, another treatment regimen has recently
come to the forefront; this treatment uses therapeutic agents, taking a medical – rather than
surgical – approach to treat BPH. Although these drug therapy strategies can result in the
abatement of symptoms over time, they do not change the proliferative or agressive nature of
the diseases and cannot completely suppress the hyperplasic mechanisms at work. From this
perspective, the main therapeutic strategy that could be effective in the treatment of the general
prostate diseases is the use of nano-based drug delivery system approach that can provide
balance by increasing apoptosis while reducing the proliferation of prostatic cells. These
innovative drug delivery systems could help men live longer, specially extending the amount
of time it took before their prostate diseases became resistant to the therapies. This
presentation will explore the latest advancements in the treatment of prostate diseases,
focusing on the effectiveness of nano-sized drug delivery strategies such as polymeric type
nanoparticles and core-shell type lipid polymer hybrid nano-sized carriers.